^
    Back
    Association details:
    Biomarker:MSI-H/dMMR
    Cancer:Endometrial Cancer
    Drug:Tevimbra (tislelizumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Solid Tumor)
    New
    Title:

    China NMPA Approves Tislelizumab for Patients with Microsatellite Instability-High or Mismatch Repair-Deficient Solid Tumors

    Excerpt:
    BeiGene, Ltd...announced that the China National Medical Products Administration (NMPA) has granted conditional approval to BeiGene’s anti-PD-1 antibody, tislelizumab, for the treatment of adult patients with advanced unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors...
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer

    Excerpt:
    ...- Patients must have deficient mismatch repair as demonstrated by lack of expression of at least 1 mismatch repair protein by immunohistochemistry, or evidence of microsatellite instability (MSI) high, or evidence of Lynch syndrome...
    Trial ID:
    NCT04906382
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Clin Lab
    Title:

    Tislelizumab Combined with Carboplatin-Paclitaxel for Treatment of Metastatic or Recurrent Endometrial Cancer: a Retrospective Clinical Study

    Published date:
    11/01/2022
    Excerpt:
    The objective response rate (ORR) was 62.5%, the disease control rate was 75.00%. The ORR was 77.78% for patients positive for PD-L1 and 69.23% for patients positive for MSI-H….Tislelizumab combined with carboplatin-paclitaxel was used as a front-line therapy, had a beneficial effect and was safe for patients with metastatic or recurrent endometrial cancer.
    Secondary therapy:
    carboplatin + paclitaxel
    DOI:
    10.7754/Clin.Lab.2022.211221